Egetis Therapeutics
7.11
SEK
+6.92 %
EGTX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+6.92%
+26.96%
+60.86%
+42.63%
+27.42%
+26.51%
+13.46%
-61.17%
-48.61%
Egetis Therapeutics is a drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Examples of the company's drug candidates are Emcitate, which is developed for patients with MCT8 deficiency, and Aladote, which is developed to reduce acute liver damage.
Read moreMarket cap
2.76B SEK
Turnover
4.56M SEK
Revenue
57.6M
EBIT %
-563.89 %
P/E
-
Dividend yield-%
-
Financial calendar
26/2
2025
Annual report '24
30/4
2025
Interim report Q1'25
6/5
2025
General meeting '24
ShowingAll content types
Egetis betonar positivt CHMP-utlåtande för Emcitate®, nyligen uppnådda betydande milstolpar och ger en bolagsuppdatering på investerardagen i Stockholm idag
Issuance and repurchase of class C shares for incentive programs
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Emission och återköp av C-aktier för incitamentsprogram
Egetis erhåller positivt CHMP-utlåtande för Emcitate® (tiratricol) för behandling av MCT8-brist
Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency
Egetis har beslutat att utvärdera RTH-beta som nästa indikation för tiratricol (Emcitate®)
Egetis has decided to explore RTH-beta as the next indication for tiratricol (Emcitate®)
Save the date: Egetis arrangerar investerardag den 18 december 2024
Save the Date: Egetis to host Investor Day on December 18, 2024
Redeye: Egetis Q3 2024: Financing secured, progress with Emcitate in US and EU
